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 Cancer predisposition syndromes (CPS), caused by germline pathogenic 
variants in tumor suppressor genes and oncogenes, are genetic conditions that 
put an individual at increased risk to develop cancer. It is estimated that 10-15% 
of children with cancer have an underlying CPS. Although genetic testing for 
these conditions has become routine in the adult setting, incorporation of 
germline genomic technologies into pediatric cancer care has not occurred as 
rapidly. The purpose of this study is to assess desire for genetic counseling and 
testing services among parents of children with cancer to provide parental 
insight in the incorporation of genomic technologies in this health care setting. 
Forty-two parents of individuals diagnosed with cancer less than 18 years of age 
completed either a paper (n=8) or online survey (n=34) regarding their child's 
cancer history, personal perspectives on genetic counseling, and 
family/demographic information. Interest in genetic testing for CPS was variable, 
with 50% of respondents indicating they would be interested in pursuing genetic 
testing for their affected child while one-third of respondents indicated that they 
were unsure if they would pursue genetic testing. The factors most commonly 
cited as impacting interest in genetic counseling/testing include the potential for 
v 
modification of medical care for family members and for the child’s treatment 
based on results. A subset of parents expressed that concerns for genetic 
discrimination and potential negative impact on mental health would negatively 
influence their interest in genetic testing for CPS. Genetic counselors have an 
ideal skillset to help families weigh the benefits and drawbacks of genetic testing 
for CPS in childhood in order to facilitate decision-making among this 
population as the availability and clinical utility of genomic testing increases. 
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1.1 Overview of pediatric cancer predisposition syndromes 
 Cancer predisposition syndromes (CPS), caused by germline pathogenic 
variants in tumor suppressor genes and oncogenes, are conditions that put an 
individual at increased risk to develop a specific set of cancers throughout their 
lifetime. CPS, also called hereditary cancer syndromes, have been recognized 
since Alfred Knudson Jr.’s 1971 publication on hereditary retinoblastoma and the 
two-hit hypothesis but have become more widely acknowledged by the medical 
community and the general public due in part to articles about the BRCA1 and 
BRCA2 genes in mainstream media as well as the availability of clinical genetic 
testing (Jolie, 2013; Knudson, 1971). Historically, scientific knowledge about 
cancer predisposition in childhood (<18 years old) was limited to the context of 
complex genetic conditions such as Beckwith-Wiedemann syndrome (BWS) and 
Down syndrome, which increase a child’s risk for embryonal tumors and 
hematologic malignancies, respectively (Clericuzio, 1999). With the advent of 
next generation sequencing (NGS) and incorporation of genetic testing for adult 
hereditary cancer syndromes into routine clinical care, cancer genetics research 
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has expanded to include the use of genomic testing for tumor and germline 
analysis in pediatric cancer populations. Through these efforts, further links 
between germline variants and increased risk of childhood cancer are becoming 
more well defined.  
It is estimated that approximately 10-15% of childhood cancers can be 
attributed to an underlying germline mutation. A study by Zhang et al. (2015) 
found an overall prevalence of germline mutations in 8.5% of patients with all 
major subtypes of childhood cancer under 20 years of age enrolled in the 
Pediatric Cancer Genome Project (PCGP). The proportion of germline mutations 
in their cohort was significantly greater than the prevalence of cancer 
predisposition syndromes in the 1000 genomes project, which was used as a 
control group (Zhang et al., 2015).  
In addition to research on germline mutations associated with cancer, 
multiple groups have performed genomic analysis of tumor samples by using 
whole exome sequencing (WES), whole transcriptome/RNA sequencing (WTS), 
and copy number analysis via microarray to identify clinically actionable 
findings in the treatment of a wide variety of childhood tumor types. Genomic 
analysis of tumors in these studies resulted in clinically actionable findings for 
between 38% and 51% of patients. For the purposes of these research projects, 
clinically actionable findings most often referred to those that would directly 
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impact medical management such as using a targeted therapy. In these studies, 
WES was also performed on germline tissues, to assess prevalence of cancer 
predisposition syndromes. Prevalence of CPS varied from 10-14%, with the 
highest prevalence identified in a cohort of children that were considered 
clinically high-risk (Chang et al., 2016; Mody et al., 2015; Oberg et al., 2016; 
Parsons et al., 2016). The inclusion criteria for each study were different, which 
may have contributed to the prevalence ranges, and the prevalence of germline 
mutations in cancer predisposition genes varied based on cancer type. 
Certain cancer types have strong associations with hereditary cancer 
predisposition syndromes, such as adrenocortical carcinoma and Li-Fraumeni 
syndrome; whereas many childhood hematologic malignancies, such as acute 
promyelocytic leukemia, are less likely to be associated with a specific cancer 
syndrome. Aside from cancer type there are a few other clues that healthcare 
providers can use to identify individuals with an inherited cancer predisposition 
syndrome, thus facilitating appropriate clinical management. Genetics 
professionals such as genetic counselors and medical geneticists combine 
information such as family history and clinical features with information about 
an individual’s tumor type, pattern and age of onset to determine the likelihood 
of a cancer predisposition syndrome (Knapke, Zelley, Nichols, Kohlmann, & 
Schiffman, 2012; Schiffman, 2012; Schiffman et al., 2013). Despite the sizable 
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prevalence of CPS among patients with childhood cancers, in 2016 there were 
only 16 pediatric cancer genetic counselors in the United States of America 
according to the Professional Status Survey of the National Society of Genetic 
Counselors (National Society of Genetic Counselors, n.d.). This means that many 
medical centers that provide childhood cancer care do not yet have genetics 
professionals integrated into their pediatric oncology departments.  
Due to these recent studies and the subsequent increasing awareness of 
childhood hereditary cancer syndromes, organizations including the Society for 
Pediatric Oncology and Hematology and members of the National Society of 
Genetic Counselors have published review articles for their members. These 
reviews provide general overviews of the types of cancer seen in childhood and 
their associations with known cancer predisposition syndromes. 
Recommendations on when to consider a childhood cancer predisposition 
syndrome, colloquially referred to as “red-flags”, are also mentioned in the 
reviews. Although these do not encompass every syndrome with childhood 
cancer risk, these articles are intended to provide succinct information about 
common cancer predisposition syndromes as well as tips for how to identify 
individuals who may benefit from genetics consultation (Ripperger et al., 2017; 




1.2 Genetic counseling referral criteria 
Although these review articles provide a general introduction to 
childhood cancer predisposition and “red-flags” that should prompt 
consideration of a genetics referral, specific referral criteria are out of the scope of 
these reviews. In one of the first studies of pediatric cancer genetic risk 
assessment, Knapke et al (2012) reviewed charts of individuals in a pediatric 
cancer survivorship clinic and determined that 29% of individuals in their cohort 
would be eligible for a genetics consultation, with pediatric cancer or family 
history of cancer as the primary referral indication (Knapke, Nagarajan, Correll, 
Kent, & Burns, 2012). In response to the Knapke study, several institutions have 
developed clinical screening tools to identify individuals at risk for childhood 
cancer predisposition syndromes that would justify referral to genetic counseling 
and/or clinical genetics. These clinical screening tools incorporate tumor type, 
clinical features, and family history to identify those individuals that would be 
most appropriate for genetics referral. 
There are three main referral tools that range in complexity and are 
variable in their approach to eliciting information. The simplest of the three is a 
one-page document published by Jongmans et al. in 2016, which provides 
general criteria that can be applied to any child with cancer (Jongmans et al., 
2016). The second referral tool, called the Tumor Predisposition Syndromes in 
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Childhood Cancer Patients (TuPS) was first developed in 2013 and revised in 
2017 by the Department of Pediatric Oncology of Emma Children's Hospital. In 
both iterations of the TuPS, clinicians are prompted to include more detailed 
information about patient and family history targeted towards specific CPS, yet 
the tool still remains applicable to all pediatric cancer types (Hopman et al., 2013; 
Postema, Hopman, de Borgie, et al., 2017). Lastly, the McGill Interactive Pediatric 
OncoGenetic Guidelines (MIPOGG) is the most specialized of the referral tools. 
The authors outlined a set of universal criteria, similar to those in the tool by 
Jongmans et al., but also provide information on the development of tumor-
specific algorithms that ultimately will be reviewed by panels of experts and 
incorporated into a mobile application (Goudie et al., 2017). Although these 
instruments vary in their approach, the three primary categories of tumor type, 
clinical features, and family history are reflected in each referral tool. 
   1.2.1 Tumor types associated with automatic referral 
Perhaps the most straightforward referral criteria captured by these 
clinical screening tools are malignancies that automatically warrant referral to a 
genetics team even in the absence of congenital anomalies or significant family 
history. The referral tools include several pediatric tumor types that 
automatically warrant genetics referral, but the number of tumor types included 
varies between 20 and 34 depending on the tool. These tumor types are selected 
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for inclusion in the referral tool based on the incidence of cancer predisposition 
syndromes among individuals diagnosed with a specific tumor type. Incidence 
to appropriately warrant automatic referral is often defined as greater than 5-
10%. 
Although not a formal referral tool, Plon and Nathanson (2005) discuss 
twelve pediatric tumor types in which there is at least a 10% incidence of cancer 
predisposition.  Among these tumor types is retinoblastoma, with the chance of a 
germline pathogenic variant in the RB1 gene up to 15% in individuals with 
unilateral disease and approaches 100% in individuals with bilateral disease. 
Other tumor types in their list include adrenocortical carcinoma (ACC), 50-80% 
of which are due to an inherited TP53 mutation resulting in a diagnosis of Li-
Fraumeni syndrome (LFS), and a host of cancers associated with 
neurofibromatosis type 1 (NF1) including juvenile myelomonocytic leukemia 
(JMML), optic pathway tumors, and malignant peripheral nerve sheath tumors 
(Plon & Nathanson, 2005). Age of tumor diagnosis is also incorporated into some 
of the tumor type criteria with the most common example being any carcinoma 
diagnosed in childhood (Jongmans et al., 2016; Postema, Hopman, Aalfs, et al., 
2017). The presence of multiple malignancies is also addressed in the referral 
tools, although their focus is divergent. In the Jongmans tool, the authors include 
comments regarding secondary malignancies that can be attributed to treatment 
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modality. The MIPOGG by Goudie et al., however, put more emphasis on 
bilateral and multifocal tumors (Goudie et al., 2017). 
   1.2.2 Clinical and family history related to genetics referral 
The incorporation of clinical features in the referral tools can be more 
challenging due to demanding clinic schedules of pediatric oncologists, and the 
fact that many pediatric cancer predisposition syndromes are not associated with 
congenital anomalies or dysmorphic features. A systematic approach to identify 
children with cancer who may have a cancer predisposition syndrome based on 
clinical features was published in 1999 by Carol Clericuzio. In the article, she 
identifies 11 categories of major and minor malformations that can be evaluated 
on physical exam and may help providers recognize the presence of a childhood 
tumor predisposition syndrome (Clericuzio, 1999). The abnormalities described 
by Clericuzio include differences in growth, various dermatologic findings, and 
abnormalities of the gastrointestinal and genitourinary tracts among others, all of 
which are associated with syndromic forms of cancer predisposition. The tool 
published by Jongmans et al. provides general guidelines for relevant clinical 
features like the categories of malformations described by Clericuzio. These 
include congenital anomalies, growth and skin abnormalities, hematological 
conditions, and immune deficiency (Jongmans et al., 2016). The TuPS screening 
instrument incorporates specific examples of clinical features which may be 
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indicative of a cancer predisposition syndrome. Each body system included on 
the tool has between one and seven distinct features to guide a targeted physical 
examination (Hopman et al., 2013; Postema, Hopman, de Borgie, et al., 2017). In 
the MIPOGG, Goudie et al. discuss the associations of specific tumor types and 
clinical features that together can be indicative of a cancer predisposition 
syndrome. Since the information gained from this approach is much more 
detailed, it is likely that the integration of clinical information into the tool 
provides a more comprehensive and targeted assessment of the utility of genetics 
referral for a given patient. However, with increased detail comes added 
complexity; this can be time consuming in already busy practices (Goudie et al., 
2017). 
All the screening instruments incorporate family history information; 
however, some are more comprehensive than others. In the simplest referral tool 
published by Jongmans et al., the family history section addresses general 
patterns, such as “a first degree relative (parent or sibling) with cancer < 45 years 
of age” and consanguinity (Jongmans et al., 2016). The universal criteria of the 
MIPOGG are comparable to the Jongmans criteria in level of detail, but 
incorporate different factors such as family member(s) with cancer in the same 
organ regardless of age (Goudie et al., 2017). The TuPS tool, however, provides 
space to include more detailed family history information. The original TuPS 
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screening instrument included in the 2013 publication by Hopman et al. has 
space to indicate both cancer and morphological abnormalities in the family. The 
revision in 2017 expanded this section by asking users to indicate ethnic 
background and prompting about non-oncologic features of the family history 
including intellectual and learning disabilities  (Hopman et al., 2013; Postema, 
Hopman, de Borgie, et al., 2017). While the information captured by the TuPS 
instrument is more comprehensive, the additional time required to complete it 
may not be practical in a clinical setting. 
1.3 Genetic counseling utility 
From a clinical perspective, identification of a pediatric cancer 
predisposition syndrome can be critical for a child’s clinical management. Like 
many adult cancer predisposition syndromes, a clinical or molecular diagnosis of 
a cancer predisposition syndrome can influence cancer screening initiation or 
frequency to either prevent or detect cancer at an earlier and more treatable 
stage. Cancer screening and management guidelines for genetic syndromes have 
been proposed in the literature as early as the 1990s, and often were embedded in 
articles discussing cancer predisposition syndromes and genetic testing 
considerations for these syndromes (Clericuzio, 1999; Strahm & Malkin, 2006; 
Teplick, Kowalski, Biegel, & Nichols, 2011). In the summer of 2017, however, 
members of the Pediatric Cancer Working Group established by the American 
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Association of Cancer Research (AACR) collaborated to publish several 
syndrome-specific management guidelines in the Clinical Cancer Research 
Pediatric Oncology Series. Screening guidelines proposed by the AACR for each 
syndrome meet a list of criteria, including the existence of effective screening 
modalities and a 5% or greater risk of developing cancer by the age of 20. These 
AACR management guidelines were published in an effort to promote 
consistency of care among pediatric oncology centers internationally (Brodeur, 
Nichols, Plon, Schiffman, & Malkin, 2017).  
Although there are several publications regarding appropriate clinical 
indications for genetics referral and management guidelines for individuals 
diagnosed with a pediatric tumor predisposition syndrome, recent research of 
physicians in pediatric oncology has demonstrated a majority of providers lack 
of comfort with the genetic testing process (Johnson et al., 2017).  This study 
identified a general lack of confidence in ordering, interpreting and discussing 
results of somatic and germline clinical genomic and exome sequencing (CGES), 
with 35% of providers expressing confidence with somatic results and 27% 
expressing confidence with germline results. Regardless of provider confidence, 
however, 93% of respondents stated a preference to include genetic counselors in 
the process of germline results disclosure. The authors concluded that even 
among specialized pediatric hematology and oncology providers at a National 
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Comprehensive Cancer Network (NCCN) facility there is a need for additional 
education and training about genomic testing and further argue in support of 
incorporating genetic counselors into the subspecialty of pediatric oncology.  
While providers indicate a preference for incorporation of genetic 
counseling into pediatric cancer care, parent interest in genetic counseling among 
this population remains unknown. Research of this type, however, has been done 
in the adult population, which can provide a framework through which to 
address this topic in the pediatric cancer population. In a systematic review, 
Willis et al (2016) identified sociodemographic, psychosocial, and clinical factors 
implicated in the utilization of genetic counseling services for adult hereditary 
cancer. Age, sex, ethnicity, socioeconomic status, and marital status are among 
the sociodemographic factors cited in their research. Psychosocial factors 
impacting uptake of genetic counseling in the adult population include 
knowledge of genetic counseling, perceived risk of cancer or a mutation, 
perceived utility, and general distress. Referral characteristics such as timing 
have also been studied in relation to genetic counseling interest and uptake. 
Studies in adult populations have demonstrated that longer length of time 
between treatment and referral, as well as poor referral timing in relation to 
treatment is associated with decreased uptake of genetic counseling services. 
Willis et al. provide a review of these findings, as well as the findings of other 
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groups who have failed to confirm the association (Willis et al., 2016). These 
factors may also impact parental interest in genetic counseling for pediatric 
cancer predisposition syndromes.  
   1.3.1 Genetic counseling considerations 
In addition to the factors identified by Willis et al., there are multiple 
unique considerations in pediatric cancer genetic testing that are not applicable 
in the adult cancer realm. For instance, genetic testing of minors is a highly-
debated topic, and it is generally agreed among healthcare professionals that 
genetic testing should not be pursued in minors unless the results would directly 
impact clinical management. This concept is often boiled down to the question, 
“is this testing in the best interest of the child?” (Kesserwan, Friedman Ross, 
Bradbury, & Nichols, 2016). Pediatric cancer predisposition syndromes often blur 
this line, as recommendations for surveillance and management of these 
conditions have previously been institution specific, prior to the publication of 
formal national guidelines. The best interest for the child can be interpreted in a 
variety of ways depending on who is asking the question. Healthcare providers 
and families have differing perspectives and will pull upon different beliefs to 
make decisions regarding genetic testing.  
Brozou et al. assessed interest in trio WES among parents of children 
recently diagnosed with cancer. Of the 94 families invited to participate, 83 
 
14 
(88.3%) consented to WES. Fear of the results was the most common reason for 
refusal among the 11 families that chose not to participate. It was concluded that 
knowledge of an underlying CPS is preferred by the majority of families 
involved in their study (Brozou et al., 2017). In the genetic counseling 
recommendations made by the AACR, Druker et al. stress the importance of pre-
test genetic counseling to ensure families have been given the information 
required in order to truly provide informed consent (Druker et al., 2017). 
Decisions about pursuing genetic testing should not only be made based on 
medical relevance but also on the psychosocial impact testing and subsequent 
changes in medical management may have on the patient and family. The age of 
the child also plays a large role in the decision of whether to pursue genetic 
testing. Whenever possible, the child should be included in the decision-making 
process, and informed assent is often required from older children.  
To further complicate the matter, genetic testing for CPS in childhood 
could also provide risk information that is not relevant until adulthood. Some 
cancer predisposition syndromes that present in childhood are caused by 
biallelic mutations in adult cancer predisposition genes, such as those in the 
mismatch repair (MMR) pathway. Heterozygous mutations in MMR genes are 
consistent with a diagnosis of Lynch syndrome, an adult onset colorectal cancer 
predisposition syndrome; however, biallelic mutations in an MMR gene are 
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consistent with a diagnosis of constitutional mismatch repair deficiency 
(CMMRD) which predisposes to multiple pediatric and adult cancer types. 
Lynch syndrome can inadvertently be diagnosed in a child if CMMRD is 
suspected and only one pathogenic mutation in a MMR gene is identified. It is 
therefore critical to introduce the possibility of inadvertently diagnosing an 
adult-onset condition in both the adult as well as the child during pre-test 
counseling. 
As next-generation sequencing becomes more affordable, many 
institutions that care for children with cancer now include tumor genomic testing 
as a tool to refine risk stratification and modify treatment. This process is often 
initiated by the patient’s primary treatment team and usually does not include 
the same informed consent process as germline genetic testing does. Tumor 
testing, however, can uncover germline status either using a germline sample for 
comparison or even based on allele frequency. Patterns of somatic mutations 
within the tumor can also be suggestive of an underlying CPS such as tumor 
hyper-mutation in individuals with a defect in the MMR pathway (Everett, 
Mody, Stoffel, & Chinnaiyan, 2016). It has been debated whether these incidental 
findings should be disclosed to patients and their families, especially when 
obtained through research protocols (Kesserwan et al., 2016). In general, 
researchers advocate incorporation of information about incidental germline 
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findings into the pre-test counseling process for testing that utilizes NGS 
technology (Kuhlen & Borkhardt, 2015). Lolkema et al. discuss the ethical, legal 
and social implications of this matter in the adult oncology setting, supporting 
return of clinically actionable results due to the ethical principle of the duty to 
warn (Lolkema et al., 2013). 
The process of results disclosure to the patient and family is also a 
complex process and can be stressful. Schneider and Jasperson advocate honest 
and age appropriate results disclosure, which is associated with better outcomes 
(Schneider & Jasperson, 2015). In contrast to results disclosure in the adult 
setting, the results of genetic testing in the pediatric oncology realm are disclosed 
to the parents or guardians of the child; depending on the patient’s age, results 
may not be initially given to them. Follow-up in adolescence is especially 
important for children diagnosed with cancer predisposition syndromes as they 
transition to managing their own care to ensure they are cognizant of their health 
risks and potential risks to future children. Return of results after the death of the 
patient also produces ethical dilemmas, although federal regulations, such as the 
Health Insurance Portability and Accountability Act (HIPAA) Privacy Rule, 
provide guidance in these situations. Scollon et al. also encourage discussion of 
post-mortem results return during the pre-test counseling process (Scollon et al., 
2015). As results of genetic testing also have an impact on other family members 
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including siblings and more distant relatives, this should be factored into the 
results disclosure process regardless of whether the patient is living or deceased. 
   1.3.2 Attitudes toward presymptomatic genetic testing 
The myriad of ethical considerations when deciding whether to pursue 
genetic testing and how to approach results disclosure continue to challenge 
health professionals and families. Although these are fundamentally personal 
decisions for families, some case studies and professional commentary have 
provided insight into decision-making about genetic testing in this population. 
Evans et al., discusses factors influencing predictive genetic testing among two 
families with Li-Fraumeni syndrome (LFS), caused by mutations in the TP53 
gene. Between the two families who elected to pursue predictive TP53 testing in 
childhood, parental anxiety was cited as the primary reason for pursuing testing 
(Evans, Lunt, Clancy, & Eeles, 2010). Although genetic testing guidelines in 
childhood discourage testing if the results would have no immediate impact on 
medical management, Michael Parker discusses scenarios in which those 
guidelines may be at odds with clinical judgement. Situations in which a 
clinician’s judgement may support genetic testing for adult-onset conditions in a 
minor include instances where it is believed that proceeding with genetic testing 
will enhance the child’s well-being. This can include suspicion for an autosomal 
recessive condition in which heterozygote carriers have increased adult cancer 
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risks such as Fanconi Anemia and CMMRD (Parker, 2010). Physicians and other 
healthcare providers must exercise caution when considering predictive testing 
for cancer predisposition syndromes in childhood and will need to incorporate 
the clinical judgement in the decision-making process. 
Parental perceptions of predictive testing in pediatric oncology have been 
explored among cohorts of individuals with a family history of familial 
adenomatous polyposis (FAP), Li-Fraumeni syndrome, neurofibromatosis type 2 
(NF2) and von Hippel Lindau (VHL). All four conditions predispose individuals 
to cancer during childhood and have some screening options available to at-risk 
individuals. Uptake of predictive testing in childhood for FAP, LFS, NF2 and 
VHL was assessed in a study by Evans et al. (1997), which showed a 95% uptake 
of genetic testing for those four conditions in children aged 10-16. Testing 
specifically for VHL was pursued for children 5-9 years of age and the rate of 
uptake in that group was 6 out of 18 (Evans, Maher, Macleod, Davies, & 
Craufurd, 1997). 
In a study of parental decision-making regarding genetic testing for 
familial TP53 variants, Alderfer et al. found that most parents elected to pursue 
genetic testing for their children at risk to inherit the variant. The perceived 
advantages to testing cited in their study included a “need to know”, a desire to 
understand why their child had cancer, and interest in research involvement. 
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Perceived disadvantages, however, were primarily focused on psychosocial 
concerns such as cancer worry and privacy or insurance concerns (Alderfer et al., 
2015). 
Among parents of children at risk for FAP, factors influencing the decision 
to pursue genetic testing included personalized medical management. Perceived 
barriers to predictive FAP testing were insurance concerns in addition to lack of 
provider recommendation, which underscores the importance of individualized 
risk assessment and discussions of medical management for individuals who are 
known to have FAP as well as those at risk (Levine et al., 2010). Although interest 
in genetic counseling and testing have been studied in individuals at risk for 
these well-known childhood cancer predisposition syndromes, these studies only 
represent a small proportion of children diagnosed with cancer who may have 
an underlying cancer predisposition syndrome. 
1.4 Rationale 
Although there are several publications regarding appropriate clinical 
indications for genetics referral in pediatric oncology, the perceived utility of 
genetic counseling from the parental perspective remains unknown. The 
pediatric oncology subspecialty provides a unique set of genetic counseling and 
testing considerations relative to other genetics specialties, including testing 
minors for adult-onset conditions and the possibility of uncovering a germline 
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cancer predisposition syndrome within the context of routine tumor testing.  
These unique considerations in pediatric cancer genetic testing have been 
discussed by genetics professionals; however, parental perspectives of genetic 
counseling and testing for the pediatric cancer population have not been 
explored. 
1.5 Purpose 
The purpose of this study is to assess desire for genetic counseling 
services among parents of children with cancer, which can be used to inform 
future genetic counseling referral practices in the pediatric oncology setting. 
Information gleaned from this study will provide genetic counselors with a 
better understanding of which patient/parent population(s) may be inherently 
more receptive to pediatric cancer genetic counseling referral. The results will 
also give a glimpse into the motivating factors in this group of families, as well as 
provide crucial information about perceived barriers to genetic counseling 
services, which in turn can be used to better meet the needs of this population. 
Administration of the study survey will also serve to increase awareness of 
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 Cancer predisposition syndromes (CPS), caused by germline pathogenic 
variants in tumor suppressor genes and oncogenes, are genetic conditions that 
put an individual at increased risk to develop cancer. It is estimated that 10-15% 
of children with cancer have an underlying CPS. Although genetic testing for 
these conditions has become routine in the adult setting, incorporation of 
germline genomic technologies into pediatric cancer care has not occurred as 
rapidly. The purpose of this study is to assess desire for genetic counseling and 
testing services among parents of children with cancer to provide parental 
insight in the incorporation of genomic technologies in this health care setting. 
Forty-two parents of individuals diagnosed with cancer less than 18 years of age 
completed either a paper (n=8) or online survey (n=34) regarding their child's 
cancer history, personal perspectives on genetic counseling, and 
family/demographic information. Interest in genetic testing for CPS was variable, 
with 50% of respondents indicating they would be interested in pursuing genetic 
testing for their affected child while one-third of respondents indicated that they 
were unsure if they would pursue genetic testing. The factors most commonly 
cited as impacting interest in genetic counseling/testing include the potential for 
modification of medical care for family members and for the child’s treatment 
based on results. A subset of parents expressed that concerns for genetic 
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discrimination and potential negative impact on mental health would negatively 
influence their interest in genetic testing for CPS. Genetic counselors have an 
ideal skillset to help families weigh the benefits and drawbacks of genetic testing 
for CPS in childhood to facilitate decision-making among this population as the 
availability and clinical utility of genomic testing increases. 
2.2 Introduction 
 Cancer predisposition syndromes (CPS) are conditions caused by 
germline pathogenic variants that put an individual at increased risk to develop 
cancer throughout their lifetime. CPS, also called hereditary cancer syndromes, 
have been recognized since Alfred Knudson Jr.’s 1971 publication on hereditary 
retinoblastoma and the two-hit hypothesis, but have become more widely 
acknowledged due in part to articles about the BRCA1 and BRCA2 genes in 
mainstream media as well as the availability of clinical genetic testing (Jolie, 
2013; Knudson, 1971). Genetic testing for CPS has become increasingly integrated 
into clinical care for adult patients, in large part due to advances in next 
generation sequencing (NGS). However, these technologies have not been as 
rapidly incorporated into routine pediatric cancer care.  
Through studies of large cohorts of children with cancer using whole 
exome sequencing (WES), it has been determined that approximately 10-15% of 
children with cancer have an underlying CPS (Chang et al., 2016; Mody et al., 
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2015; Oberg et al., 2016; Parsons et al., 2016; Zhang et al., 2015). In addition to the 
general prevalence of CPS, relationships have been established between specific 
pediatric tumor types and germline genetic changes. For example, 
retinoblastoma is highly associated with pathogenic changes in the RB1 gene, 
with pathogenic variants identified in 15% of patients with unilateral 
retinoblastoma and nearly 100% of patients with bilateral disease (Plon & 
Nathanson, 2005). Despite the prevalence of CPS among patients with pediatric 
cancers and the established associations between cancer types and specific 
genetic changes, many medical centers do not yet have genetics professionals 
integrated into their pediatric oncology departments.  
 Childhood CPS have, however, begun to receive more attention from the 
medical community in the form of review articles published by Society for 
Pediatric Oncology and Hematology as well as the National Society of Genetic 
Counselors (Ripperger et al., 2017; Scollon et al., 2017). In addition to increasing 
attention to these syndromes, several institutions have developed clinical 
screening tools to identify individuals at risk for childhood cancer predisposition 
syndromes that would justify referral to genetic counseling and/or clinical 
genetics. These clinical screening tools incorporate tumor type, clinical features, 
and family history with or without dysmorphology evaluation to select those 
individuals that would be most appropriate for genetics referral (Goudie et al., 
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2017; Hopman et al., 2013; Jongmans et al., 2016; Postema, Hopman, de Borgie, et 
al., 2017). 
 Although there are several publications regarding appropriate clinical 
indications for genetics referral, the perceived utility of genetic counseling from 
the parental perspective remains unknown. Formal guidelines for treatment and 
management of specific CPS were published in the summer 2017 Clinical Cancer 
Research Pediatric Oncology Series to promote uniformity of care in this patient 
population (Brodeur et al., 2017). With the increasing attention on pediatric CPS, 
studies have been done to assess provider interest in and comfort with 
incorporating genetic/genomic testing into childhood cancer care. These studies 
have demonstrated a lack of comfort with the process of genetic testing and an 
interest in incorporating genetic counselors into this aspect of cancer care 
(Johnson et al., 2017). Despite the push to incorporate genomic testing into 
pediatric cancer care from the scientific and medical communities, little is known 
about parental perspectives on this topic. 
In addition to limited provider comfort and uncertainty surrounding 
parent interest in these technologies, there are several other genetic counseling 
considerations in the realm of pediatric cancer. Historically, genetic testing for 
cancer predisposition and other adult-onset conditions in minors has been 
discouraged due to the principles of autonomy and right to an open future 
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(Kesserwan et al., 2016). Pediatric CPS genetic testing falls in an ethical grey-
zone, as genes implicated in childhood CPS overlap with adult-onset hereditary 
cancer syndromes. Germline genetic status can also be identified incidentally 
during routine tumor genetic profiling, which is used for risk assessment and 
treatment decisions. This produces an ethical dilemma for providers in 
determining whether to disclose these results to families since somatic tumor 
testing does not have a rigorous consent process like germline genomic testing 
(Everett et al., 2016).  
As genetic testing for pediatric cancer predisposition syndromes becomes 
more accessible, it will be critical incorporate the technology in a thoughtful 
manner due to the associated ethical complexities. One step towards this end is 
to gain a deeper understanding of parental attitudes toward genomic 
technologies among the pediatric cancer population. The purpose of this study is 
to assess desire for genetic counseling services including motivating factors and 
perceived barriers to genetic counseling and testing among parents of children 
with cancer. It is anticipated that most parents surveyed will be interested in 
genetic counseling and/or testing for their child.  Among the factors influencing 
interest in pediatric cancer genetic counseling, it is expected that prior 
knowledge of genetic counseling, desire for additional information regarding 
medical management, and perceived cost will play the largest role in predicting 
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parental desire for genetic counseling services. As one of the first steps to 
promoting awareness of CPS among patients and providers, this research may in 
turn promote access to specialized care for individuals with these rare pediatric 
cancer predisposition syndromes in the future.  
2.3 Materials and Methods 
   2.3.1 Design and Participants 
 Both paper and online surveys were conducted to assess attitudes towards 
genetic counseling and testing among parents of children diagnosed with cancer 
younger than 18 years of age. Participants were recruited in person at the 
Palmetto Health Children's Center for Cancer & Blood Disorders clinic during 
the check-in process for routine office visits. Eligible individuals were given a 
copy of the questionnaire (Appendix A) as well as a participant resource sheet 
that provided additional information about genetic counseling (Appendix B). 
The online questionnaire (Appendix C) was posted on Facebook parent support 
pages by representatives of “Alex’s Lemonade Stand Foundation” 
(www.alexslemonade.org) and “St. Baldricks Foundation” 
(www.stbaldricks.org) in order to maintain anonymity of the members of each of 
these parent support pages. 
Responses were collected from October 1st, 2017 until March 1st, 2018. 
Inclusion criteria for participation consisted of individuals over 18 years old who 
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are the parent or legal guardian of a child diagnosed with any type of cancer. 
Any parents who were less than 18 years of age at the time of data collection 
were excluded from participation. A total of forty-two responses were obtained 
via paper (n=8) and online (n=34) versions of the questionnaire that met inclusion 
criteria for the study. An additional 6 paper and 2 online survey responses were 
obtained but did not meet the inclusion criteria because an insufficient number of 
questions were answered (n=3), a cancer diagnosis was not indicated (n=2), 
and/or a patient completed the questionnaire instead of a parent (n=4).  
   2.3.2 Instrument 
 The questionnaire consisted of twenty-four and thirty-four questions for 
the paper and online versions respectively. Differences in the number of 
questions were necessitated by the format of the online survey program 
(SurveyMonkey), but the text was maintained between the two delivery models. 
Survey items were divided into four sections comprising cancer history, 
perspective on genetic counseling, information about your child/children, and 
demographic information. The survey instrument was reviewed and edited by 
all members of the committee prior to submission to the Institutional Review 
Board (IRB). Informed consent was implied by completion of the questionnaire in 




   2.3.3 Data Analysis 
 Both quantitative and qualitative data were captured in survey responses. 
Numerical and categorical responses from the questionnaire were analyzed 
using descriptive statistics. Chi-square tests for association were used to 
determine significance (p < 0.05) of the association between both patient and 
parent demographics and parental perspectives on genetic counseling/testing. 
Factors influencing interest in genetic counseling/testing were assessed using a 
Likert-type scale (1=strongly disagree; 5=strongly agree) and were represented 
with descriptive statistics. Lastly, responses to open-ended questions were 
assigned themes and sub-themes by the principal investigator and reviewed by 
the committee members. 
2.4 Results 
   2.4.1 Demographic Information 
 Of the fifty individuals who initiated the questionnaire, data were 
analyzed for the forty-two participants who both met the inclusion criteria and 
responded to enough survey items (>50%). Demographic characteristics of the 
participants are summarized in Table 2.1, which demonstrates that the sample 
population consisted of mostly female (82.9%; n=34) and Caucasian (80.5%;  
n=33) participants. Ages of the sample population ranged from 31 to 64 years, 
with a mean age of 43.78 years. Most participants reported an education level of  
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Characteristics Frequency Percent 
Sex (n=41) 
Male 7 17.1% 
Female 34 82.9% 
Age (n=40)   
31-40y 16 40.0% 
41-50y 17 42.5% 
51-60y 6 15.0% 
61-70y 1 2.5% 
Race/Ethnicity (n=41) 
Caucasian 33 80.5% 
Hispanic/Latin American 1 2.4% 
Black 3 7.3% 
Asian/Pacific Islander 2 4.9% 
Biracial 2 4.9% 
Education Level (n=41) 
Some high school 1 2.4% 
High school or GED 1 2.4% 
Some college 8 19.5% 
Associate degree 4 9.8% 
Bachelor degree 11 26.8% 
Graduate degree 16 39.0% 
Annual Household Income (n=41) 
Less than $25,000 3 7.3% 
$25,001-$50,000 3 7.3% 
$50,001-$75,000 7 17.1% 
$75,001-$100,000 10 24.4% 
More than $100,000 14 34.1% 
Prefer not to respond 4 9.8% 
Region of Residence (n=40) 
Northeast 16 40.0% 
Southeast 15 37.5% 
West 9 22.5% 
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a Bachelor’s degree or higher (65.8%; n=27) and annual household income greater 
than $75,000 (58.5%; n=24); however, all education levels and annual income 
categories were represented in the sample. Most participants also reported that 
they are married (77.5%; n=31). Fifteen different states of residence were 
reported, with most participants residing in the northeast [CT, NJ, NY, PA and 
RI] (40.0%; n=16) or southeast [FL, GA, NC, SC and VA] (37.5%; n=15) United 
States. Due to the limited number of participants from states that are not on the 
east coast, the remaining states were categorized as west [AZ, CA, HI, WA and 
WI] (22.5%; n=9). 
2.4.2 Cancer Diagnoses 
 Participants were asked to provide information about their child who was 
diagnosed with cancer, which is summarized in Table 2.2. Among the reported 
childhood cancer diagnoses, most affected individuals were male  
 (64.3%; n=27). Average age at diagnosis was 5.26 years, ranged from 1 to 16 
years, and most children were living at the time of the study (88.1%; n=37). On 
average, children were 6.71 years from diagnosis; however, time since diagnosis 
ranged from 0-19 years. The cancers reported by participants via a free-text 
response were sorted into three categories: hematologic (35.7%; n=15), nervous 
system (38.1%; n=16) and solid cancers (26.2%; n=11) that were approximately 
equally represented. In addition, two children were diagnosed with more than   
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Table 2.2 Cancer history and demographic characteristics of the child[ren] 
diagnosed with cancer. 
 
Characteristics Frequency Percent 
Sex (n=42) 
Male 27 64.3% 
Female 15 35.7% 
Age at Diagnosis (n=41)   
Infancy 4 9.8% 
Toddler 9 22.0% 
Preschool 8 19.5% 
Early Childhood 13 31.7% 
Middle Childhood 1 2.4% 
Adolescence 6 14.6% 
Current Age (n=35) 
Toddler 1 2.9% 
Preschool 2 5.7% 
Early Childhood 10 28.6% 
Middle Childhood 7 20.0% 
Adolescence 11 31.4% 
Adult 4 11.4% 
Living or Deceased (n=42) 
Living 37 88.1% 
Deceased 5 11.9% 
Cancer Type (n=42) 
Hematologic Malignancies 15 35.7% 
Solid Tumor 11 26.2% 
Nervous System Tumor 16 38.1% 
Number of Malignancies (n=42) 
One 40 4.8% 
Two or More 2 95.2% 
Siblings (n=41) 
None 8 19.5% 
One 18 43.9% 




one cancer. Participants also provided information about other medical and/or 
special needs of their child with cancer. Of the 42 children with cancer, 57.1% 
(n=24) have no additional medical needs aside from cancer treatment. The 
remaining 18 children had a total of 26 pre-existing or treatment-related health 
complications depicted in Figure 2.1, the most common of which was learning 
difficulties (n=7). 
Information about cancers in first degree relatives (FDR) and second 
degree relatives (SDR) of the child with cancer was also collected and outlined in 
Table 2.3. Of all participants, 64% reported that their child had a family history of 
cancer (n=27). Two participants reported a family history of other childhood 
cancers; these were acute lymphoblastic leukemia and choroid plexus carcinoma. 
Approximately 10% of respondents (n=4) indicated that a parent or sibling of 
their child was diagnosed with cancer <45 years of age, and 26% (n=11) reported 
a grandparent, aunt, or uncle was diagnosed with cancer <45 years of age. 
Among first and second-degree relatives, the most common cancer type was 
breast cancer (n=8) followed by prostate (n=3) and skin (n=2) cancers. Multiple 
other cancer types were indicated in family members, and five participants 
provided history for more distant relatives such as third and fourth degree in the 






























Figure 2.1 Other reported medical and/or special needs of the children with cancer. 
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Table 2.3 Family history characteristics of the children diagnosed with cancer. 
 
  
Family History Characteristics    Frequency Percent 
Reported Family History 
1 or more childhood cancers 2 4.8% 
1 or more FDR with cancer <45 years 4 9.5% 
2 or more SDR with cancer <45 years 11 26.2% 
Childhood Cancers  
Acute lymphoblastic leukemia 1 2.4% 
Choroid plexus, brain tumor 1 2.4% 
FDR Cancer Type 
Breast 2 33.33% 
Sarcoma 1 16.67% 
Lymphoma 1 16.67% 
Thyroid 1 16.67% 
Skin 1 16.67% 
SDR Cancer Type 
Breast 6 46.15% 
Prostate 3 23.08% 
Brain 1 7.69% 
Skin 1 7.69% 
Leukemia 1 7.69% 
Ovarian 1 7.69% 
Jongmans Criteria  
Meets Criteria 18 42.9% 
Does not meet criteria 24 57.1% 
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The five criteria for genetics referral proposed by Jongmans et al. (2016) 
were used to determine those participants most likely to benefit from cancer 
genetic counseling and/or testing. These criteria include: (1) family history of 
cancer, (2) specific cancer types, (3) two or more malignancies, (4) other 
anomalies or features, and (5) excessive treatment toxicity (Jongmans et al., 2016). 
Information from participant report was used to determine whether the criteria 
were met. Based on the information provided about the child and family’s cancer 
histories, 42.9% (n=18) of participants met the referral criteria outlined in 
Appendix D. 
In addition to cancer history, participants were asked about medical 
conditions for their other children. In contrast with the 42.9% (n=18) of children 
with cancer who had additional medical and/or special needs, 9.6% (n=4) 
reported the child with cancer had a sibling with additional medical and/or 
special needs. These included 2 individuals with autism spectrum disorder, 1 
with chronic sinus infections due to nasal polyps, and 1 with von Willebrand 
disease. 
   2.4.3 Perspective on Genetic Counseling 
Prior awareness, experience and interest in genetic counseling was 
assessed in the section of the questionnaire that followed the child’s cancer 




reported awareness of genetic counseling prior to participating in the 
questionnaire. Of the individuals who reported prior awareness, 17 participants 
reported that they were offered genetic counseling (40.5%), two of which 
declined (4.8%). The reasons for genetic counseling referral were provided via 
free-text response and assigned one of the three common referral indications: 
prenatal, cancer or general genetics. Most participants who were offered genetic 
counseling reported the referral indication as cancer (52.9%; n=9); however, 
others reported either prenatal (29.4%; n=5) or general (17.6%; n=3) indications 
for genetics referral. Examples of non-cancer related referrals included advanced 
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Figure 2.2 Participant perspectives on genetic counseling and/or testing. (A) 
knowledge of genetic counseling prior to participation in the study; (B) 
previous experience with genetic counseling and/or testing regardless of 




evaluation for Marfan syndrome. These non-cancer related indications accounted 
for 47.0% of genetic counseling referrals reported among participants. 
Participants were also asked about their interest in genetic counseling for 
their child’s cancer history. While half (50.0%; n=21) of participants reported 
interest in pursuing genetic counseling and/or testing for pediatric cancer 
indications, 31.0% (n=13) of participants reported they were unsure. Less than 
20% (n=7) of participants reported no interest in genetic testing. 
   2.4.4 Factors Influencing Interest in Genetic Counseling/Testing 
In addition to general interest in pursuing genetic testing, participants 
were presented with seven statements about factors that might influence their 
interest in genetic counseling/testing. For each statement, participants were 
asked to rank the level of influence that the factor would have on their interest in 
pursuing genetic counseling/testing. Each statement had a range of responses on 
a numerical scale from 1-5; the averages of responses were all greater than 3 
(Figure 2.3). The statement with the highest mean score was “if it would impact 
my family members’/my own healthcare” (mean = 4.64), while “If my child’s 
treatment was complete” had the lowest mean at 3.38.  
Participants were also asked what the ideal age would be for pursuing 
genetic counseling and testing for their child. Over one-third of participants 




counseling/testing. Of participants that responded to the question about timing 
(n=25), 28.0% indicated uncertainty (n=7). Most responses did not specify a 
certain age range, rather they indicated that testing could be pursued at any age 
(n=5) or when needed (n=7) which accounts for 48.0% of responses. Of those that 
specified a certain age range, there was not a clear preference for testing in 
childhood (7.1%; n=3) or waiting until adulthood (4.8%; n=2).  
Trends emerged between groups regarding interest in genetic counseling 
and/or testing with three different demographic factors. These factors were the 
child’s age at diagnosis, sex of the child, and the average household income. A 
0 1 2 3 4 5 6
If my child’s treatment was complete
If my child was older
If I could use the information for family
planning
If the test was free/low cost
If my doctor recommended it
If the information might affect my child’s 
treatment




Figure 2.3 Average ratings of factors influencing interest in genetic 
counseling/testing (1=strongly disagree; 5=strongly agree). 
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chi-square test for association was conducted that demonstrated a statistically 
significant association between the child’s age at diagnosis and interest in genetic 
counseling (p=0.021). Interest in genetic counseling among each age group at 
diagnosis is represented in Figure 2.4. The highest proportion of parents who 
were interested in genetic counseling/testing was among parents of children  
diagnosed as toddlers (35.0%), whereas parents of children diagnosed as 
adolescents accounted for the smallest proportion of those interested in genetic 
counseling (10.0%). The greatest uncertainty regarding interest in genetic 
counseling/testing was among parents of children diagnosed in early childhood 
























Figure 2.4 Relationship between age of the child's cancer diagnosis and 
interest in genetic counseling/testing. 
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reported that they were not interested in pursuing genetic counseling and/or 
testing. Age at diagnosis was compared with participant ranking of the 
statement “I would be interested in genetic counseling if my child was older.” 
However, no statistical significant association was identified between the two 
variables. In contrast with the statistically significant association between age at 
diagnosis and interest in genetic counseling/testing, there was no evidence of an 
association between the child’s current age (p=0.60), or the duration of time since 
diagnosis (p=0.80) and interest in genetic counseling/testing. 
Another statistically significant finding by chi-square test for association 
was between the child’s sex and interest in genetic counseling (p=0.039). Interest 
in genetic counseling stratified by child’s sex is illustrated in Figure 2.5. Parents  
of female children with cancer were more likely to be interested in genetic 
counseling/testing (52.4%) than parents of male children with cancer (47.6%). 
Lack of interest in and uncertainty about genetic counseling/testing were more 
common among parents of male children with cancer. All the individuals who 
reported that they were not interested in genetic counseling/testing were parents 
of male children with cancer. Of those that reported uncertainty regarding  
genetic counseling/testing, 69.2% were parents of males with cancer. The child’s 
sex was compared with participant ranking of the statement “I would be 




planning.” However, no statistical significant association was identified between 
the two variables.  
Participant annual income also demonstrated a statistically significant 
association with interest in genetic counseling and/or testing (p=0.050). Interest in 
genetic counseling broken down by annual income is illustrated in Figure 2.6. A  
higher proportion of individuals who replied “Yes” regarding interest in genetic 
counseling/testing reported annual income less than $100,000 (70.0%) as  
compared with those who reported annual income greater than $100,000 (30.0%). 
In contrast, 35.7% of participants who reported annual income greater than 



























counseling/testing, which accounted for 83.3% of the total respondents who 
replied “No” regarding interest in genetic counseling/testing. There was no 
statistical association between annual income and participant responses to the 
statement “I would be interested in genetic counseling if the test was free/low 
cost.” No statistically significant difference in prior knowledge of or experience 
with genetic counseling was identified between participants who made less than 
or equal to $100,000 and greater than $100,000 annually. 
Chi-square tests for association were done for all other demographic 
factors and interest in genetic counseling/testing except for participant sex, race, 





















Figure 2.6 Relationship between participant annual income and interest 
in genetic counseling/testing. 
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responses in these categories. These analyses showed no statistically significant 
associations. Of note, interest in genetic counseling/testing appeared to be 
independent from whether the child met the Jongman’s criteria for genetics 
referral (p=0.981). No statically significant association was observed between 
prior knowledge of genetic counseling and interest (p=0.668). 
   2.4.5 Thematic Analysis 
Within the questionnaire, participants were asked to provide their thoughts 
regarding genetic counseling and testing for pediatric cancer predisposition in a 
free-text format. Of the total participants, 50% (n=21) responded to this question; 
however, two of the responses were excluded from thematic analysis because 
they did not provide insight into their reasoning for or against interest in 
pursuing genetic testing. Themes are broken down into motivators and barriers, 
which are then further broken down into sub-themes. The sub-themes are 
organized by observation frequency, which is demonstrated in Table 2.4 and 
Figure 2.7. Select quotations are provided to illustrate each theme. 
   2.4.5.1 Motivators for genetic counseling and/or testing. 
 Most participants who responded to the free-text question described 
positive factors influencing their interest in genetic counseling and/or testing 
(n=14). Among the responses, two distinct themes emerged: (1) general   
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Table 2.4 Themes and sub-themes regarding interest in genetic counseling/ 




Theme  Sub-themes 
Motivators for Genetic 
Counseling and/or 
Testing 
General knowledge for family members or other 
individuals 
Potential utility in treatment, surveillance and/or 
planning for the child’s future 
Barriers to Genetic 
Counseling and /or 
Testing 
Perceived susceptibility to genetic discrimination 
in health insurance/employment or issues of 
confidentiality  
Concerns regarding impact of genetic testing 
results on mental health 
































Figure 2.7 Frequency of sub-themes identified through analysis of the 
free-text question responses.  
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knowledge for family members or other individuals, and (2) potential utility in 
treatment, surveillance, and/or planning for the child’s future.  
Theme 1: General knowledge for family members or other individuals 
 The most commonly described factor influencing interest in genetic 
counseling and testing among free-text responses was the desire for knowledge 
that could help others. Over 50% (n=10) of the free-text responses for this 
question drew upon the theme of knowledge for others. Some individuals 
mentioned an interest in gaining the information for their immediate family, 
while others touched on the desire to help other individuals such as through 
research. 
“I would be willing to do it if it helped my family or anyone else” 
Theme 2: Potential utility in treatment, surveillance and/or planning for the child’s 
future 
 Several individuals highlighted how information gained through genetic 
counseling and/or testing could be useful for their child’s future. Participants 
expressed uncertainty and concern for their child’s future, mentioning that 
information gained from genetic testing may help them to determine appropriate 
surveillance. 
“I want to know if my sons [sic] cancer has a genetic link or if he holds a 
predisposition for other cancers. It would allivieate [sic] some of our fears and 
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worry. What if we stop scanning and he gets cancer again? We might not know 
till it’s too late. If we had genetic testing we would know what to do for the 
future.” 
 Others highlight the desire for additional information about options for 
cancer prevention.  
“If we could have learned earlier about risks or possible preventative measures, we 
would have participated.” 
   2.4.5.2 Barriers to genetic counseling and/or testing. 
Approximately a quarter (n=5) of responses to the free-text question 
identified barriers to genetic counseling or testing in this population. Three 
themes emerged including: (1) perceived susceptibility to genetic discrimination 
in health insurance/employment or issues of confidentiality, (2) concerns 
regarding impact of genetic testing results on mental health, and (3) cost 
prohibitive nature of genetic/genomic testing. 
Theme 1: Perceived susceptibility to genetic discrimination in health 
insurance/employment or issues of confidentiality 
 A topic of concern brought up by participants (n=3) was the potential for 
genetic discrimination and issues of confidentiality. One participant discussed 
their fears that genetic information could be used to deny health insurance 
coverage for treatment, saying:  
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“…Also concerned about health insurance companies misusing the information to 
deny treatment or coverage.” 
Another parent brought up the sensitivity of genetic information in our 
current society, which is contrasted by their desire to contribute to medical 
knowledge.  
“I understand the value of pooling genetic information, but security and 
confidentiality can no longer be guaranteed in our society. Sharing personal 
information without a definite benefit and the distinct possibility of adverse 
consequences make it hard to do.” 
Theme 2: Concerns regarding impact of genetic testing results on mental health 
The subject of mental health implications of genetic testing results was 
also a concern identified by a participant. 
“cloud hanging over your head and might affect mental health and outlook on 
life.” 
Theme 3: Cost prohibitive nature of genetic/genomic testing 
Genetic testing can not only be taxing on financial resources, but also 
other resources such as tumor tissue as was identified by one participant: 
“We didn't pursue due to cost and because they don't have much left of the tumor 
so we wanted to save it in case he needs treatment in the future.” 
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Overall, participants provide more insight into the motivating factors 
(n=14) relative to insight about barriers (n=5). 
2.5 Discussion 
The incorporation of genetic and genomic testing in pediatric oncology has 
lagged in its adoption in the adult oncology setting; however, recent research has 
supported the clinical utility of NGS technologies in the pediatric population. A 
study of provider comfort with genomic testing demonstrated a lack of comfort 
and an interest in incorporating genetic counselors into the testing process 
(Johnson et al., 2017). Genetic counselors are trained in providing education and 
genetic risk assessment, and can serve as a resource for families in the decision-
making process surrounding genetic testing. 
   2.5.1 Parental Attitudes Towards Genetic Counseling 
  It was hypothesized that most participants would be interested in genetic 
counseling/testing; however, only half responded that they were interested in 
pursuing genetic testing for their child. The participant population demonstrated 
more uncertainty regarding interest in genetic testing for their child than was 
expected, with 31.0% reporting they were unsure of their interest. Genetic 
counselors have an ideal skillset to assist families who are contemplating 
whether to pursue genetic testing for their child by providing information and 
support in the decision-making process. Of all participants, 16.7% reported that 
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they were not interested in genetic testing. However, genetic counseling may still 
be beneficial as their reasoning for lack of interest was not clearly established 
through this study. Research by Brozou et al. demonstrated a much higher rate of 
uptake of WES in families of children with cancer at 88.3%.  However, this was 
assessed after the WES consent process, so it may be that the counseling process 
alleviated uncertainty leading to uptake of WES (Brozou et al., 2017). 
No clear consensus was reached in the sample about an optimal age or 
timing for genetics referral. Forty-eight percent of participants who responded to 
the question about timing indicated that genetic testing should be performed 
either "when needed" or "at any time". Therefore, the results from this study 
suggest that parental preference regarding timing is not contrary to the genetic 
counselor recommendations provided by Druker et al. in the AACR Pediatric 
Oncology Series, which encouraged referral at the time of diagnosis (Druker et 
al., 2017). 
 Interest in genetic testing for cancer predisposition syndromes (CPS) 
among this population was independent of personal or family history 
characteristics suggestive of a CPS as defined by the Jongmans criteria for 
genetics referral. It is potentially reasonable then, to offer genetics referral 
regardless of history, as other research has suggested that family history may not 
be a reliable tool in assessing the likelihood of a CPS. In a study by Zhang et al., 
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only a minority of individuals with a germline pathogenic variant in a gene 
associated with a known CPS had a suggestive family history (Zhang et al., 
2015). Age-related penetrance of CPS and the potential for de novo mutations, 
especially in syndromic forms of CPS, may impact the utility of family history in 
genetic risk assessment for pediatric CPS.  
   2.5.2 Factors Influencing Attitudes Toward Genetic Counseling 
 Contrary to the hypothesis, no statistically significant association was 
observed between prior knowledge of genetic counseling and interest in 
pursuing genetic counseling/testing for pediatric CPS. Factors that show 
statistically significant association with interest in genetic testing were the child’s 
age at diagnosis and sex, as well as the participant’s annual household income. 
There was a trend towards decreased interest in genetic testing as the child’s age 
at diagnosis increased. These findings are inconsistent with results from a 1997 
study, which showed uptake of predictive testing for FAP, LFS, NF2 and VHL 
was 95% among children 10-16 years of age, while uptake of VHL testing from 
ages 5-9 was only 6 out of 18 (Evans et al., 1997). It is difficult to ascertain why 
these findings were inconsistent.  However, the differences between predictive 
and diagnostic testing as well as the time since publication of the study by Evans 
et al. may be contributory. 
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 Another factor associated with interest in genetic testing was the child’s 
sex. None of the parents of female children diagnosed with cancer indicated that 
they were not interested in genetic testing. It was hypothesized that this may be 
due to the potential use of genetic information in the child’s family planning, 
although no statistical significance was found with the statement “I would be 
interested in genetic counseling if I could use the information for family 
planning.” Since this statement was aimed at participant (i.e. the parent) as 
opposed to their child, it cannot be assumed that participants were not interested 
in pursuing genetic testing for the child’s future family planning. Other studies 
have demonstrated similar associations between uptake or interest in genetic 
counseling/testing and sex in both the adult and pediatric cancer populations 
(Evans et al., 1997; Willis et al., 2016). 
 Annual income was also a factor that influenced interest in genetic testing. 
However, instead of increased interest with higher annual income as expected, 
an inverse association was observed. Prior knowledge of or experience with 
genetic counseling and/or testing did not differ significantly between income 
groups and thus cannot account for the identified association between income 
and genetic counseling/testing interest. In addition, there was not a statistically 
significant association between annual income and ranking of the statement “I 
would be interested in genetic counseling if the test was free/low cost.” The sub-
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theme “cost prohibitive nature of genetic/genomic testing” was only identified in 
one free-text response, which was less than expected. What then, are the factors 
that influenced the disparate interest levels between participants in the over 
$100,000 and under $100,000 groups? It may be that individuals who have an 
annual household income greater than $100,000 have a heightened concern for 
the potential for genetic discrimination and concerns of confidentiality. The 
“perceived susceptibility to genetic discrimination in health 
insurance/employment or issues of confidentiality” sub-theme was the most 
identified barrier to genetic counseling and testing among free-text responses. 
Further research would be useful to clarify which factors influence the observed 
reduction of interest among parents with an annual income greater that $100,000. 
 Among the factors influencing interest in genetic counseling/testing 
assessed via the Likert-scale, the two with the highest average ranking were “if it 
would impact my family members’/my own healthcare” and “if the information 
might affect my child’s treatment.” These echo the sentiment identified by 
multiple individuals in the free-text responses. Themes observed from the free-
test responses focused on the utility of genetic testing results for the child, their 
family, and others. Many individuals indicated that they would be interested in 
pursuing genetic counseling/testing if the information could be used to help 
family members. Others discuss the merits of general knowledge and/or the 
 
54 
benefits for research purposes. Several participants mentioned their interest in 
the ability to use information from genetic counseling/testing for their child’s 
treatment and surveillance. 
   2.5.3 Implications for Practice 
 Parental perspectives on genetic counseling and testing in the pediatric 
cancer population gained from this study complement the pre-existing medical 
literature on CPS in childhood. Results from this study support the perceived 
utility of genetic counseling and testing by parents of children diagnosed with 
cancer as well as the perceived barriers to uptake of these technologies. Genetic 
counselors have specialized training that can be used to engage families and 
assist in weighing the benefits and drawbacks of genetic testing for CPS in 
childhood. Parental interest in genetic/genomic technology, previously 
demonstrated lack of provider comfort, and the currently limited number of 
pediatric cancer genetics professionals support further expansion of genetics 
professionals into childhood cancer care.  
2.6 Limitations and Future Studies 
   2.6.1 Study Limitations 
A major limitation of this study was the small sample size and homogenous 
participant population. Initially, the survey was administered solely on paper in 
the Palmetto Health Children's Center for Cancer & Blood Disorders clinic to 
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obtain a participant population that is representative of families impacted by 
pediatric cancer in South Carolina. Due to a low response rate, an online version 
of the questionnaire was generated and distributed via Facebook parent support 
pages. The smaller subset of participants that responded via paper questionnaire 
showed more diversity in multiple demographics categories. Due to the 
homogeneity of participant demographics, several demographic categories were 
excluded from chi-square association tests. These categories included participant 
sex, race, educational level, and marital status. 
In addition to sample size, another unanticipated limitation was the 
wording certain questions, such as those in the Likert-scale. It is possible that no 
associations were found between responses to the Likert-questions and the 
statistically significant associations between genetic counseling/testing interest 
and child’s age/child’s sex, since the Likert questions were directed at the 
participant rather than their child with cancer. Due to the question wording, 
factors influencing desire for genetic counseling/testing as they relate to the child 
with cancer may not have been accurately assessed. 
   2.6.2 Future Studies 
 As there were significant limitations regarding sample size, these research 
questions should be assessed again in a larger and more diverse population. This 
may be feasible through recruitment in a larger pediatric cancer treatment center. 
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It would also be informative to compare interest in genetic testing prior to and 
after pre-test counseling to see how counseling impacts participant interest in 
pursuing genetic testing. Additional research questions that can be considered 
include referral timing in the context of the cancer treatment process, as well as 
investigation into why certain groups are less receptive to genetic counseling and 
testing, such as families who make greater than $100,000 annually. It would also 
be prudent to investigate the association between age at diagnosis and interest in 
genetic counseling/testing as it relates to the child’s autonomy. This information 
is critical for genetic counselors to optimize the information and support 
provided to families throughout the genetic testing process. For the individuals 
who reported uncertainty about pursuing genetic testing, qualitative studies may 
illuminate the primary source(s) of ambivalence. In turn, these insights will 





Alderfer, M. A., Zelley, K., Lindell, R. B., Novokmet, A., Mai, P. L., Garber, J. E., 
… Nichols, K. E. (2015). Parent decision-making around the genetic testing 
of children for germline TP53 mutations. Cancer, 121(2), 286–293. 
https://doi.org/10.1002/cncr.29027 
Brodeur, G. M., Nichols, K. E., Plon, S. E., Schiffman, J. D., & Malkin, D. (2017). 
Pediatric Cancer Predisposition and Surveillance: An Overview, and a 
Tribute to Alfred G. Knudson Jr. Clinical Cancer Research: An Official Journal 
of the American Association for Cancer Research, 23(11), e1–e5. 
https://doi.org/10.1158/1078-0432.CCR-17-0702 
Brozou, T., Taeubner, J., Velleuer, E., Dugas, M., Wieczorek, D., Borkhardt, A., & 
Kuhlen, M. (2017). Genetic predisposition in children with cancer – 
affected families’ acceptance of Trio-WES. European Journal of Pediatrics, 1–
8. https://doi.org/10.1007/s00431-017-2997-6 
Chang, W., Brohl, A. S., Patidar, R., Sindiri, S., Shern, J. F., Wei, J. S., … Khan, J. 
(2016). MultiDimensional ClinOmics for Precision Therapy of Children 
and Adolescent Young Adults with Relapsed and Refractory Cancer: A 
Report from the Center for Cancer Research. Clinical Cancer Research: An 
 
58 
Official Journal of the American Association for Cancer Research, 22(15), 3810–
3820. https://doi.org/10.1158/1078-0432.CCR-15-2717 
Clericuzio, C. L. (1999). Recognition and management of childhood cancer 
syndromes: A systems approach. American Journal of Medical Genetics, 
89(2), 81–90. https://doi.org/10.1002/(SICI)1096-
8628(19990625)89:2<81::AID-AJMG5>3.0.CO;2-I 
Druker, H., Zelley, K., McGee, R. B., Scollon, S. R., Kohlmann, W. K., Schneider, 
K. A., & Wolfe Schneider, K. (2017). Genetic Counselor Recommendations 
for Cancer Predisposition Evaluation and Surveillance in the Pediatric 
Oncology Patient. Clinical Cancer Research: An Official Journal of the 
American Association for Cancer Research, 23(13), e91–e97. 
https://doi.org/10.1158/1078-0432.CCR-17-0834 
Evans, D. G., Lunt, P., Clancy, T., & Eeles, R. (2010). Childhood predictive genetic 
testing for Li-Fraumeni syndrome. Familial Cancer, 9(1), 65–69. 
https://doi.org/10.1007/s10689-009-9245-9 
Evans, D. G., Maher, E. R., Macleod, R., Davies, D. R., & Craufurd, D. (1997). 
Uptake of genetic testing for cancer predisposition. Journal of Medical 
Genetics, 34(9), 746–748. 
Everett, J. N., Mody, R. J., Stoffel, E. M., & Chinnaiyan, A. M. (2016). 
Incorporating genetic counseling into clinical care for children and 
 
59 
adolescents with cancer. Future Oncology (London, England), 12(7), 883–886. 
https://doi.org/10.2217/fon-2015-0022 
Goudie, C., Coltin, H., Witkowski, L., Mourad, S., Malkin, D., & Foulkes, W. D. 
(2017). The McGill Interactive Pediatric OncoGenetic Guidelines: An 
approach to identifying pediatric oncology patients most likely to benefit 
from a genetic evaluation. Pediatric Blood & Cancer. 
https://doi.org/10.1002/pbc.26441 
Hopman, S. M. J., Merks, J. H. M., de Borgie, C. A. J. M., Aalfs, C. M., Biesecker, 
L. G., Cole, T., … Hennekam, R. C. M. (2013). The development of a 
clinical screening instrument for tumour predisposition syndromes in 
childhood cancer patients. European Journal of Cancer (Oxford, England: 
1990), 49(15), 3247–3254. https://doi.org/10.1016/j.ejca.2013.06.015 
Johnson, L.-M., Valdez, J. M., Quinn, E. A., Sykes, A. D., McGee, R. B., Nuccio, R., 
… Mandrell, B. N. (2017). Integrating next-generation sequencing into 
pediatric oncology practice: An assessment of physician confidence and 
understanding of clinical genomics. Cancer, 123(12), 2352–2359. 
https://doi.org/10.1002/cncr.30581 
Jolie, A. (2013, May 14). My Medical Choice. The New York Times, p. A25. 
Jongmans, M. C. J., Loeffen, J. L. C. M., Waanders, E., Hoogerbrugge, P. M., 
Ligtenberg, M. J. L., Kuiper, R. P., & Hoogerbrugge, N. (2016). Recognition 
 
60 
of genetic predisposition in pediatric cancer patients: An easy-to-use 
selection tool. European Journal of Medical Genetics, 59(3), 116–125. 
https://doi.org/10.1016/j.ejmg.2016.01.008 
Kesserwan, C., Friedman Ross, L., Bradbury, A. R., & Nichols, K. E. (2016). The 
Advantages and Challenges of Testing Children for Heritable 
Predisposition to Cancer. American Society of Clinical Oncology Educational 
Book. American Society of Clinical Oncology. Meeting, 35, 251–269. 
https://doi.org/10.14694/EDBK_160621 
Knapke, S., Nagarajan, R., Correll, J., Kent, D., & Burns, K. (2012). Hereditary 
cancer risk assessment in a pediatric oncology follow-up clinic. Pediatric 
Blood & Cancer, 58(1), 85–89. https://doi.org/10.1002/pbc.23283 
Knapke, S., Zelley, K., Nichols, K. E., Kohlmann, W., & Schiffman, J. D. (2012). 
Identification, management, and evaluation of children with cancer-
predisposition syndromes. American Society of Clinical Oncology Educational 
Book. American Society of Clinical Oncology. Meeting, 576–584. 
https://doi.org/10.14694/EdBook_AM.2012.32.576 
Knudson, A. G. (1971). Mutation and cancer: statistical study of retinoblastoma. 
Proceedings of the National Academy of Sciences of the United States of America, 
68(4), 820–823. 
Kuhlen, M., & Borkhardt, A. (2015). Cancer susceptibility syndromes in children 
 
61 
in the area of broad clinical use of massive parallel sequencing. European 
Journal of Pediatrics, 174(8), 987–997. https://doi.org/10.1007/s00431-015-
2565-x 
Laerd Statistics (2016). Chi-square test for association using SPSS Statistics. 
Statistical tutorials and software guides. Retrieved from 
https://statistics.laerd.com/ 
Levine, F. R., Coxworth, J. E., Stevenson, D. A., Tuohy, T., Burt, R. W., & Kinney, 
A. Y. (2010). Parental attitudes, beliefs, and perceptions about genetic 
testing for FAP and colorectal cancer surveillance in minors. Journal of 
Genetic Counseling, 19(3), 269–279. https://doi.org/10.1007/s10897-010-9285-
1 
Lolkema, M. P., Gadellaa-van Hooijdonk, C. G., Bredenoord, A. L., Kapitein, P., 
Roach, N., Cuppen, E., … Voest, E. E. (2013). Ethical, Legal, and 
Counseling Challenges Surrounding the Return of Genetic Results in 
Oncology. Journal of Clinical Oncology, 31(15), 1842–1848. 
https://doi.org/10.1200/JCO.2012.45.2789 
Mody, R. J., Wu, Y.-M., Lonigro, R. J., Cao, X., Roychowdhury, S., Vats, P., … 
Chinnaiyan, A. M. (2015). Integrative Clinical Sequencing in the 




National Society of Genetic Counselors. (n.d.). 2016 Professional Status Survey: 
Salary & Benefits (p. 70). 
Oberg, J. A., Glade Bender, J. L., Sulis, M. L., Pendrick, D., Sireci, A. N., Hsiao, S. 
J., … Kung, A. L. (2016). Implementation of next generation sequencing 
into pediatric hematology-oncology practice: moving beyond actionable 
alterations. Genome Medicine, 8(1), 133. https://doi.org/10.1186/s13073-016-
0389-6 
Parker, M. (2010). Genetic testing in children and young people. Familial Cancer, 
9(1), 15–18. https://doi.org/10.1007/s10689-009-9272-6 
Parsons, D. W., Roy, A., Yang, Y., Wang, T., Scollon, S., Bergstrom, K., … Plon, S. 
E. (2016). Diagnostic Yield of Clinical Tumor and Germline Whole-Exome 
Sequencing for Children With Solid Tumors. JAMA Oncology. 
https://doi.org/10.1001/jamaoncol.2015.5699 
Plon, S. E., & Nathanson, K. (2005). Inherited susceptibility for pediatric cancer. 
Cancer Journal (Sudbury, Mass.), 11(4), 255–267. 
Postema, F. A. M., Hopman, S. M. J., Aalfs, C. M., Berger, L. P. V., Bleeker, F. E., 
Dommering, C. J., … Merks, J. H. M. (2017). Childhood tumours with a 
high probability of being part of a tumour predisposition syndrome; 
reason for referral for genetic consultation. European Journal of Cancer 
(Oxford, England: 1990), 80, 48–54. https://doi.org/10.1016/j.ejca.2017.04.021 
 
63 
Postema, F. A. M., Hopman, S. M. J., de Borgie, C. A. J. M., Hammond, P., 
Hennekam, R. C., Merks, J. H. M., … TuPS study group. (2017). Validation 
of a clinical screening instrument for tumour predisposition syndromes in 
patients with childhood cancer (TuPS): protocol for a prospective, 
observational, multicentre study. BMJ Open, 7(1), e013237. 
https://doi.org/10.1136/bmjopen-2016-013237 
Ripperger, T., Bielack, S. S., Borkhardt, A., Brecht, I. B., Burkhardt, B., Calaminus, 
G., … Kratz, C. P. (2017). Childhood cancer predisposition syndromes-A 
concise review and recommendations by the Cancer Predisposition 
Working Group of the Society for Pediatric Oncology and Hematology. 
American Journal of Medical Genetics Part A. 
https://doi.org/10.1002/ajmg.a.38142 
Saletta, F., Dalla Pozza, L., & Byrne, J. A. (2015). Genetic causes of cancer 
predisposition in children and adolescents. Translational Pediatrics, 4(2), 
67–75. https://doi.org/10.3978/j.issn.2224-4336.2015.04.08 
Schiffman, J. D. (2012). Hereditary cancer syndromes: if you look, you will find 
them. Pediatric Blood & Cancer, 58(1), 5–6. https://doi.org/10.1002/pbc.23336 
Schiffman, J. D., Geller, J. I., Mundt, E., Means, A., Means, L., & Means, V. (2013). 
Update on pediatric cancer predisposition syndromes. Pediatric Blood & 
Cancer, 60(8), 1247–1252. https://doi.org/10.1002/pbc.24555 
 
64 
Schneider, K. W., & Jasperson, K. (2015). Unique Genetic Counseling 
Considerations in the Pediatric Oncology Setting. Current Genetic Medicine 
Reports, 3(2), 65–73. https://doi.org/10.1007/s40142-015-0064-z 
Scollon, S., Anglin, A. K., Thomas, M., Turner, J. T., & Schneider, K. W. (2017). A 
Comprehensive Review of Pediatric Tumors and Associated Cancer 
Predisposition Syndromes. Journal of Genetic Counseling, 26(3), 387–434. 
https://doi.org/10.1007/s10897-017-0077-8 
Scollon, S., Bergstrom, K., McCullough, L. B., McGuire, A. L., Gutierrez, S., 
Kerstein, R., … Plon, S. E. (2015). Pediatric Cancer Genetics Research and 
an Evolving Preventive Ethics Approach for Return of Results after Death 
of the Subject. The Journal of Law, Medicine & Ethics: A Journal of the 
American Society of Law, Medicine & Ethics, 43(3), 529–537. 
https://doi.org/10.1111/jlme.12295 
Strahm, B., & Malkin, D. (2006). Hereditary cancer predisposition in children: 
genetic basis and clinical implications. International Journal of Cancer, 
119(9), 2001–2006. https://doi.org/10.1002/ijc.21962 
Teplick, A., Kowalski, M., Biegel, J. A., & Nichols, K. E. (2011). Educational 
paper: screening in cancer predisposition syndromes: guidelines for the 




Willis, A. M., Smith, S. K., Meiser, B., Ballinger, M. L., Thomas, D. M., & Young, 
M.-A. (2016). Sociodemographic, psychosocial and clinical factors 
associated with uptake of genetic counselling for hereditary cancer: a 
systematic review. Clinical Genetics. https://doi.org/10.1111/cge.12868 
Zhang, J., Walsh, M. F., Wu, G., Edmonson, M. N., Gruber, T. A., Easton, J., … 
Downing, J. R. (2015). Germline Mutations in Predisposition Genes in 




APPENDIX A – PAPER QUESTIONNAIRE 
The following coversheet and questionnaire were distributed to 





   
PARENTAL INTEREST IN GENETIC 
COUNSELING IN THE PEDIATRIC 
ONCOLOGY SETTING. 
      
PURPOSE AND BACKGROUND:  
You are being asked to volunteer for a research study conducted by Lauren Desrosiers, a 
graduate student in the Department of Genetic Counseling at the University of South 
Carolina. The purpose of this study is to assess interest in genetic counseling among parents 
of children diagnosed with cancer. You are being asked to participate in this study because 
your child has a current or previous diagnosis of cancer.  
 
PROCEDURES:  
If you agree to participate in this study, you will be asked to complete a questionnaire 
about your familiarity with and interest in genetic counseling, although no prior knowledge 
of genetic counseling is required. You will also be asked to provide information about your 
family, including your child’s medical history pertaining to their diagnosis of cancer. Upon 




Participation in the study will take approximately 5-15 minutes. 
 
PAYMENT TO PARTICIPANTS:  
You will not be paid for participating in this study.   
 
VOLUNTARY PARTICIPATION: 
Participation in this research study is voluntary. You are free not to participate, or to stop 
participation at any time, for any reason without negative consequences. You are not 
required to answer any question you do not wish to answer. In the event that you do 
withdraw from this study, the information you have already provided will be kept in a 
confidential manner. 
 




If you are willing to be contacted for future research please provide your name and contact 
information below. 
Name: _____________________________________________________________________ 





Please answer the following questions regarding your child who has/had cancer. 
 




Prefer not to respond
2. What type of cancer were they diagnosed with? _________________________________
3. How old was your child when they were diagnosed with cancer? _________ 
4. Has your child been diagnosed with more than one cancer? If yes, what other cancers? 
Yes; Please specify type(s) and age(s) at 
diagnosis: __________________________________ 
 No
5. Is your child living or deceased? 
Living: Current Age _____ Deceased: Age of Death: ______ 








Skin differences: _____________________________ 
Blood condition(s): ___________________________ 
Frequent infections 
Other: _____________________________________
7. Is there a history of cancer in the family?
Yes No 
8. If you selected “Yes” for question 7 above, please select all that apply. Please also provide the type of cancer and 
age at diagnosis for each selection made below.  
 There are 1 or more cancers in childhood (younger than18 years old): ___________________________________  
  Your child has a parent or sibling with cancer less than 45 years of age: _________________________________  
 There are 2 or more grandparents or aunts/uncles with cancer diagnosed before 45 years of age (on the same 
side of the family): _______________________________________________________________________________ 
 
Perspective on Genetic Counseling 
Genetic counselors are trained health care workers that help people understand the role of genetic factors in disease. They use family 
and personal medical histories to determine a person’s risk of having a genetic change that would increase their chance of having 
cancer. These changes can cause hereditary cancer syndromes, which may explain why a person developed cancer, and can also give 
risk information for family members. 
 
9. Have you heard of genetic counseling before beginning this survey?
Yes No Unsure
10. Have you or your child had genetic counseling or genetic testing before? (Please select the best answer)
Yes: For what reason? _____________________ 
No 
Unsure 
I was offered genetic counseling or testing, but chose 
not to accept: For what reason? 
_____________________________________________
11. Is genetic testing for hereditary cancer something you would be interested in pursuing for/with your child?
Yes No Unsure
12. Please indicate how each of the following statements would impact your interest in genetic counseling or testing 
with 1=strongly disagree and 5=strongly agree. I would be interested in genetic counseling… 
        Strongly Disagree             Strongly Agree 
         1 2 3 4 5 
i. If my doctor recommended it          
ii. If the information might affect my child’s treatment        
iii. If it would impact my family members’/my own healthcare      




v. If my child was older           
a. What is the best age for genetic counseling or testing? __________ 
vi. If my child’s treatment was complete         
vii. If the test was free/low cost           
viii. Other, please specify: ____________________________      




Information about your child/children 
Please answer the following questions about all of your children.  
 
14. How many children do you have? __________ 
15. How old are your children? Please provide ages for each of them. _________________________________________








Skin differences: _____________________________ 





Please complete the following questions. This section helps to classify responses among subsets of the population and will not be 
used in any attempts to identify you. 
 




Prefer not to respond
18. How old are you? _____ 





American Indian or Alaskan Native 
Other, Please specify: _________________________
20. What is the highest level of education you have completed?
Some high school 









In a domestic partnership or civil union 
Single, but living with a significant other 
Single/Never married 
22. What was your total household income last year?




More than $100,000 
Prefer not to respond
23. What is your zip-code? __________ 
24. What type of health insurance do you have for your child(ren)?
Private insurance plan (Ex. Aetna, Cigna, etc.) 
Medicaid/Medicare 
 Other, Please specify: _________________________ 
No Insurance
Thank you! This concludes the survey. We appreciate your participation. Please refer to accompanying flyer for more details on 
hereditary cancer and genetic counseling. 
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APPENDIX B – PARTICIPANT RESOURCES 
The following participant resources sheet was distributed to interested 
participants in the Palmetto Health Children's Center for Cancer & Blood 
Disorders clinic. It was also distributed electronically to individuals who were 




What is Hereditary Cancer? 
Most cancers are considered sporadic, which means that they happen by 
chance. Unlike sporadic cancer, hereditary cancers are those that happen 
because of a genetic change a person is born with that makes them more likely 
to develop cancer. There are many genes that help our bodies prevent cancer, 
and changes in those genes can make a person more susceptible to cancer. 
Researchers have found that up to 10% of children with cancer have a gene 
change that increased their risk of developing cancer. On their own, genetic 
changes do not guarantee that a person will develop cancer, but knowing 
about these can help doctors recommend ways to modify environmental 
factors or detect cancer earlier.  
 
What is a Genetic Counselor? 
Genetic counselors are trained health care workers that help people 
understand the role of genetic factors in disease. They use family and personal 
medical histories to determine a person’s risk of having a genetic change that 
would increase their chance of having cancer. These changes can cause 
hereditary cancer syndromes, which may explain why a person developed 
cancer, and can also give risk information for family members. Cancer genetic 
counselors help families to decide whether genetic testing for these types of 
changes is right for them. 
 
Additional Information 
If you are interested in additional information about genetic counseling and/or 
testing please see the “Locate a Genetic Counselor” section on the back of this 
document. You may also speak with your child’s physician, or contact the 
University of South Carolina Genetic Counseling department at 803-545-5775 




Locate a Genetic Counselor 
If at any point during this questionnaire you became concerned about your 
child’s chance of having a genetic mutation that would increase their risk of 
having cancer, consider contacting a genetic counselor by following the steps 
below: 
1. Go to the National Society of Genetic Counselors website homepage at: 
www.nsgc.org 
2. On the NSGC homepage, click the link titled, “Find a Genetic Counselor” 
 
3. Enter your postal code and make sure to click “Cancer” under specialization. 




APPENDIX C – ONLINE QUESTIONNAIRE 
 The text below was used to recruit participants via Facebook support 
groups. Staff members from “Alex’s Lemonade Stand Foundation” and “St. 
Baldricks Foundation” were asked to post this email on the support pages on my 
behalf in order to protect the privacy of members. 
“Hello, 
My name is Lauren Desrosiers and I am a master's candidate in the 
University of South Carolina genetic counseling training program. For my 
master's research project, I am studying interest in genetic counseling 
among parents of children with cancer. 
If you are a parent or legal guardian of a child who was diagnosed with 
cancer under the age of 18, please consider completing my questionnaire 
to study parental interest as well as factors influencing interest in genetic 
counseling and testing services in this parent population. This 




The link took participants to the online questionnaire on SurveyMonkey.com, 
which can be seen in subsequent pages.  
 
74 
Thank you for your interest in participating in my master's research project. Please review the
study details below prior to completing this survey.
Welcome!
PURPOSE AND BACKGROUND: 
You are being asked to volunteer for a research study conducted by Lauren Desrosiers, a graduate student in the Department of
Genetic Counseling at the University of South Carolina. The purpose of this study is to assess interest in genetic counseling among
parents of children diagnosed with cancer. You are being asked to participate in this study because your child has a current or previous
diagnosis of cancer. 
PROCEDURES: 
If you agree to participate in this study, you will be asked to complete a questionnaire about your familiarity with and interest in genetic
counseling, although no prior knowledge of genetic counseling is required. You will also be asked to provide information about your
family, including your child’s medical history pertaining to their diagnosis of cancer.
DURATION: 
Participation in the study will take approximately 5-15 minutes.
PAYMENT TO PARTICIPANTS: 
You will not be paid for participating in this study.  
VOLUNTARY PARTICIPATION:
Participation in this research study is voluntary. You are free not to participate, or to stop participation at any time, for any reason
without negative consequences. You are not required to answer any question you do not wish to answer. In the event that you do
withdraw from this study, the information you have already provided will be kept in a confidential manner.
If you have any questions, please contact Lauren Desrosiers by phone (803-545-5775) or email (lauren.desrosiers@uscmed.sc.edu).
1. Are you above the age of 18?
Yes
No







Please answer the following questions regarding your child who has/had cancer.
Cancer History




Prefer not to respond
4. What type of cancer were they diagnosed with?
5. How old was your child when they were diagnosed with cancer?









Please answer the following questions regarding your child who has/had cancer.
Cancer History












Please answer the following questions regarding your child who has/had cancer.
Cancer History









Genetic counselors are trained health care workers that help people understand the role of genetic
factors in disease. They use family and personal medical histories to determine a person’s risk of
having a genetic change that would increase their chance of having cancer. These changes can
cause hereditary cancer syndromes, which may explain why a person developed cancer, and can
also give risk information for family members.
Perspective on Genetic Counseling
















Genetic counselors are trained health care workers that help people understand the role of genetic
factors in disease. They use family and personal medical histories to determine a person’s risk of
having a genetic change that would increase their chance of having cancer. These changes can
cause hereditary cancer syndromes, which may explain why a person developed cancer, and can
also give risk information for family members.
Perspective on Genetic Counseling





 Strongly Disagree Strongly Agree
If my doctor
recommended it
If the information might
affect my child’s
treatment
If it would impact my
family members’/my
own healthcare
If I could use the
information for family
planning
If my child was older
If my child’s treatment
was complete
If the test was free/low
cost
Other (please specify)
19. Please indicate how each of the following statements would impact your interest in genetic counseling
or testing with 1=strongly disagree and 5=strongly agree. I would be interested in genetic counseling…










Please complete the following questions. This section helps to classify responses among subsets
of the population and will not be used in any attempts to identify you.
Demographic Information




Prefer not to respond
27. How old are you?





American Indian or Alaskan Native
Other (please specify)
29. What is the highest level of education you have completed?
Some high school












In a domestic partnership or civil union
Single, but living with a significant other
Single/Never married






Prefer not to respond
32. What type of health insurance do you have for your child(ren)?









APPENDIX D – JONGMANS ET AL. GENETICS REFERRAL CRITERIA 
The referral criteria used to identify whether participants had personal or family 
history characteristics suggestive of a CPS was developed by researchers from 
the Netherlands and published in the journal article cited below. The article is 
published under a Creative Commons license, which permits reproduction of 
Figure 1 from their paper on the subsequent page. 
 
Jongmans, M. C. J., Loeffen, J. L. C. M., Waanders, E., Hoogerbrugge, P. M., 
Ligtenberg, M. J. L., Kuiper, R. P., & Hoogerbrugge, N. (2016). Recognition 
of genetic predisposition in pediatric cancer patients: An easy-to-use 
selection tool. European Journal of Medical Genetics, 59(3), 116–125. 
https://doi.org/10.1016/j.ejmg.2016.01.008 
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